血漿プロテオーム探索に関する会議 - 概要
概要 |
ショートコース |
1日目 |
2日目 |
3日目
アジェンダ (英語PDF)
8回目の血漿プロテオーム探索に関する会議は生物学的痕跡の発見、開発、検証に関する技術的課題、戦略、固有のフェーズとプロセスについて取り上げます。
Comprehensive,
systematic characterization of the plasma
proteome in healthy and diseased states greatly
facilitates the development of biosignatures for
early disease detection, clinical diagnosis, and
therapy. However, blood plasma is the most
complex human-derived proteome containing other
tissue proteome subsets as well as a wide
dynamic range of protein concentrations.
Therefore, the characterization of biosignatures
in the human plasma proteome is a very
complicated task. This is due in part to the
lack of a coherent pipeline connecting
biosignature discovery with well-established
methods for validation. Cambridge Healthtech
Institute’s 8th Annual Mining the Plasma
Proteome addresses the challenges and
strategies of these inherent phases and
processes for biosignature discovery and
development.
What
is the best tool to reach your research goal?
Mass Spectrometry, Protein Arrays,
Chromatography, Data Analysis and
Interpretation?
Advances
in methods and technology for profiling plasma
proteins now enable construction of a
comprehensive pipeline from:
Scientific
Advisory Committee
N. Leigh Anderson, Ph.D., Founder & CEO,
Plasma Proteome Institute
Daniel Chelsky, Ph.D., CSO, Caprion
Pharmaceuticals
Jerald S. Feitelson, Ph.D., Business Development
Manager, Discovery Products Business Center,
Beckman Coulter, Inc.
Karin Hughes, Ph.D., Worldwide Product
Director-Sepsis, Stroke & Protein C, ,
Biosite Inc.
Karin Rodland, Ph.D., Science Lead, NIH
Programs, Biological Sciences Division, Pacific
Northwest National Laboratory
